Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other financing activities (2017 - 2021)

Aclaris Therapeutics has reported Other financing activities over the past 5 years, most recently at $300000.0 for Q2 2021.

  • Quarterly results put Other financing activities at $300000.0 for Q2 2021, up 164.79% from a year ago — trailing twelve months through Jun 2021 was -$289000.0 (up 30.53% YoY), and the annual figure for FY2024 was -$377000.0, down 4612.5%.
  • Other financing activities for Q2 2021 was $300000.0 at Aclaris Therapeutics, up from -$31000.0 in the prior quarter.
  • Over the last five years, Other financing activities for ACRS hit a ceiling of $378000.0 in Q1 2018 and a floor of -$753000.0 in Q4 2017.
  • Median Other financing activities over the past 5 years was -$53500.0 (2018), compared with a mean of -$89500.0.
  • Biggest five-year swings in Other financing activities: surged 251.32% in 2019 and later crashed 2472.22% in 2020.
  • Aclaris Therapeutics' Other financing activities stood at -$753000.0 in 2017, then skyrocketed by 89.91% to -$76000.0 in 2018, then surged by 251.32% to $115000.0 in 2019, then tumbled by 126.96% to -$31000.0 in 2020, then surged by 1067.74% to $300000.0 in 2021.
  • The last three reported values for Other financing activities were $300000.0 (Q2 2021), -$31000.0 (Q4 2020), and -$95000.0 (Q3 2020) per Business Quant data.